173 related articles for article (PubMed ID: 34911674)
1. Nivolumab-induced multiple morphea associated with eosinophilic fasciitis.
Lacombe M; Bedane C; Delaumenie S; Bernard P
Eur J Dermatol; 2021 Dec; 31(6):844-846. PubMed ID: 34911674
[No Abstract] [Full Text] [Related]
2. Eosinophilic fasciitis and lichen sclerosus in a patient treated with nivolumab.
Andrés-Lencina JJ; Burillo-Martínez S; Aragón-Miguel R; Calleja-Algarra A; Rodríguez-Peralto JL; Ortiz-Romero PL; Gargallo-Moneva V
Australas J Dermatol; 2018 Nov; 59(4):e302-e304. PubMed ID: 29797309
[No Abstract] [Full Text] [Related]
3. Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response.
Toussaint F; Hammon M; Erdmann M; Moreira A; Kirchberger MC; Schuler G; Schett G; Heinzerling L
Rheumatology (Oxford); 2019 Oct; 58(10):1875-1877. PubMed ID: 31056673
[No Abstract] [Full Text] [Related]
4. Nivolumab induced morphea.
Dal Bello G; Rosina P; Colato C; Girolomoni G
G Ital Dermatol Venereol; 2020 Oct; 155(5):701-702. PubMed ID: 30295447
[No Abstract] [Full Text] [Related]
5. Subcutaneous sclerosis with fasciitis and eosinophilia after phytonadione injections.
Janin-Mercier A; Mosser C; Souteyrand P; Bourges M
Arch Dermatol; 1985 Nov; 121(11):1421-3. PubMed ID: 2932062
[TBL] [Abstract][Full Text] [Related]
6. Vitiligo-like lesions developing upon immune checkpoint inhibition in advanced melanoma.
Grän F; Emmerich K; Mohme S; Goebeler M; Gesierich A
Eur J Dermatol; 2020 Feb; 30(1):72-73. PubMed ID: 32250264
[No Abstract] [Full Text] [Related]
7. Nivolumab-induced plaque morphea in a malign melanoma patient.
Acar A; Oraloglu G; Yaman B; Karaarslan I
J Cosmet Dermatol; 2021 Aug; 20(8):2645-2647. PubMed ID: 33355973
[TBL] [Abstract][Full Text] [Related]
8. Dual checkpoint inhibitor-associated eosinophilic enteritis.
Yang J; Lagana SM; Saenger YM; Carvajal RD
J Immunother Cancer; 2019 Nov; 7(1):310. PubMed ID: 31730503
[TBL] [Abstract][Full Text] [Related]
9. De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: A retrospective analysis.
Bui AN; Singer S; Hirner J; Cunningham-Bussel AC; Larocca C; Merola JF; Lian CG; LeBoeuf NR
J Am Acad Dermatol; 2021 Mar; 84(3):864-869. PubMed ID: 33323344
[No Abstract] [Full Text] [Related]
10. Genital lichen sclerosus after nivolumab.
Miraglia E; Soda G; Giustini S
Dermatol Online J; 2020 Nov; 26(11):. PubMed ID: 33342187
[No Abstract] [Full Text] [Related]
11. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma.
Cho M; Nonomura Y; Kaku Y; Nakabo S; Endo Y; Otsuka A; Kabashima K
J Dermatol; 2019 Jan; 46(1):e43-e44. PubMed ID: 29863795
[No Abstract] [Full Text] [Related]
12. An Original Case of an Association of Eosinophilic Fasciitis with Cholangitis Induced by Nivolumab.
Le Tallec E; Ricordel C; Triquet L; Deniel A; Marcorelles P; Lena H; Jego P; Belhomme N
J Thorac Oncol; 2019 Jan; 14(1):e13-e15. PubMed ID: 30579548
[No Abstract] [Full Text] [Related]
13. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
[No Abstract] [Full Text] [Related]
14. L-tryptophan ingestion associated with eosinophilic fasciitis but not progressive systemic sclerosis.
Freundlich B; Werth VP; Rook AH; O'Connor CR; Schumacher HR; Leyden JJ; Stolley PD
Ann Intern Med; 1990 May; 112(10):758-62. PubMed ID: 2331120
[TBL] [Abstract][Full Text] [Related]
15. A rare case of eosinophilic gastritis induced by nivolumab therapy for metastatic melanoma.
Tsuji A; Hiramatsu K; Namikawa S; Yamamoto A; Midori Y; Murata Y; Tanaka T; Nosaka T; Naito T; Takahashi K; Ofuji K; Matsuda H; Ohtani M; Imamura Y; Iino S; Hasegawa M; Nakamoto Y
Clin J Gastroenterol; 2022 Oct; 15(5):876-880. PubMed ID: 35978213
[TBL] [Abstract][Full Text] [Related]
16. Systemic Scleroderma Induced by Nivolumab in Malignant Melanoma.
Loupret T; Boisseau R; Lopez JG; Bertin P; Vergne-Salle P
In Vivo; 2024; 38(3):1451-1453. PubMed ID: 38688588
[TBL] [Abstract][Full Text] [Related]
17. Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis.
Falanga V; Medsger TA
J Am Acad Dermatol; 1987 Oct; 17(4):648-56. PubMed ID: 3668010
[TBL] [Abstract][Full Text] [Related]
18. Eosinophilia-myalgia syndrome.
Troy JL
Mayo Clin Proc; 1991 May; 66(5):535-8. PubMed ID: 2030620
[No Abstract] [Full Text] [Related]
19. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
Messer A; Drozd B; Glitza IC; Lu H; Patel AB
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
[TBL] [Abstract][Full Text] [Related]
20. Generalised morphea induced by pembrolizumab.
Herrscher H; Tomasic G; Castro Gordon A
Eur J Cancer; 2019 Jul; 116():178-181. PubMed ID: 31202088
[No Abstract] [Full Text] [Related]
[Next] [New Search]
